Hefei Jiunuo Pharmaceutical Technology

Hefei Jiunuo Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Hefei, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on high-value targets within the fields of oncology and immunology to address significant unmet medical needs. Its lead candidate, JN-001, is a highly selective Bruton's tyrosine kinase (BTK) inhibitor currently in Phase 1 clinical trials for the treatment of B-cell malignancies. By leveraging its expertise in medicinal chemistry, Hefei Jiunuo aims to develop next-generation targeted therapies with superior safety and efficacy profiles compared to existing treatments.